Last reviewed · How we verify

Cravit based triple therapy

National Taiwan University Hospital · FDA-approved active Small molecule Quality 1/100

Cravit based triple therapy is a Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved.

At a glance

Generic nameCravit based triple therapy
SponsorNational Taiwan University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cravit based triple therapy

What is Cravit based triple therapy?

Cravit based triple therapy is a Small molecule drug developed by National Taiwan University Hospital.

Who makes Cravit based triple therapy?

Cravit based triple therapy is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What development phase is Cravit based triple therapy in?

Cravit based triple therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing